title: [Clinical Analysis of Priming Regimen for Treatment of Acute Myeloid Leukemia (Non-APL) Patients Aged over 70 Years].
abstract: OBJECTIVE
  To explore the therapeutic efficacy for patients aged over 70 years with acute myeloid leukemia(non-APL).
  
  
  METHODS
  Clinical data of 19 acute myeloid leukemia patients aged over 70 years admitted in our hospital from March 2006 to April 2016 years were analyzed retrospectively. Among them 15 patients received priming regimen and 4 patients received best supportive treatment. The overall survival time between patients with priming regimen and patients with best supportine treatment was compared by Kaplan-Meier analysis. The prognostic factors were evaluated by using multivariate analysis. Out of the 19 patients, 9 were males and 10 were females, with median age of 75 years (70-84).
  
  
  RESULTS
  After 2 cycles of induction chemotherapy, the complete response rate was (7/15)46.6% and overall response rate was (11/15) 73%. Significant longer median survival time was observed in priming regimen group, compared with that in best supportive treatment group (11 months vs 2 months)(χ2=17.077, P<0.001). The patients were well tolerant to side-effect of chemotherapy. Multivariate analysis showed that only receiving induction chemotherapy or not was the independent prognostic factor of the survival time(P<0.05), while the sex, age, ECOG index, CD34, HLA-DR, WBC count and ratio of blast cells in bone marrow were factor affecting the prognosis.
  
  
  CONCLUSIONS
  The priming regimen may be practicable and effective for the treatment of patients with acute myeloid leukemia aged over 70 years (non-APL) and prolong the survival time of these patients.
authors.affiliation: Department of Hematology/Oncology, The First Hospital of Tsinghua University, Beijing 100016, China. E-mail:gzx2962@outlook.com.
authors.forename: Zhen-Xing
authors.initials: ZX
authors.lastname: Guo
authors.affiliation: Department of Hematology/Oncology, The First Hospital of Tsinghua University, Beijing 100016, China.
authors.forename: Li
authors.initials: L
authors.lastname: Liu
authors.affiliation: Department of Hematology/Oncology, The First Hospital of Tsinghua University, Beijing 100016, China.
authors.forename: Xiu-Hong
authors.initials: XH
authors.lastname: Ren
authors.affiliation: Department of Hematology/Oncology, The First Hospital of Tsinghua University, Beijing 100016, China.
authors.forename: Ping-Ping
authors.initials: PP
authors.lastname: Liu
authors.affiliation: Department of Hematology/Oncology, The First Hospital of Tsinghua University, Beijing 100016, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Hematology/Oncology, The First Hospital of Tsinghua University, Beijing 100016, China.
authors.forename: Li
authors.initials: L
authors.lastname: Zheng
authors.affiliation: Department of Hematology/Oncology, The First Hospital of Tsinghua University, Beijing 100016, China.
authors.forename: Song-Song
authors.initials: SS
authors.lastname: Zhang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols; D001853:Bone Marrow; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute; D007958:Leukocyte Count; D008297:Male; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies